Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Head & Neck Cancer Research Report Site Specific Group Meeting Tuesday 9th June 2015 Maxine Taylor Senior Research Delivery Manager Delivering clinical research to make patients, and the NHS, better Content of report • • • • Overview of network changes Overview of research activity New studies for the portfolio Request for research lead 2 Introduction • NIHR Clinical Research Network merged all cancer research networks with all other clinical research networks in England on 1st April 2014 • CRN - West of England is one of 15 new networks • This new geography does not map exactly to the site specific group geography. It now includes Gloucestershire and Swindon but no longer includes Taunton and Yeovil • Taunton and Yeovil are served by the CRN – South West Peninsula • I will work closely with my counterpart in South West Peninsula to support this SSG in full 3 Map showing the 15 Clinical Research Networks in England West of England • Population 2.4 million • - Budget £13.2 million • - 7 Acute Trusts • - 2 Mental Health Trusts • - CCL Principal Treatment Centre • - Full team only since December 2014 • - Small core support team based at host in Bristol • Research will follow patient pathways regardless of network geography Purpose of the network • Translation of national workstreams and objectives (generic and specialty specific) with strategic oversight of research activity within the geography of CRN - West of England in terms of: – Portfolio • Balance, new studies, feasibility, industry trials – Performance • Targets, support timely set up, support timely recruitment – People • Skill mix, workforce flexibility, resources, training 5 CRN - West of England Management Model • Division 1 • Division 5 Maxine Taylor Mary Griffin Senior RDM Workforce Development RDM RM&G and Industry Mary Perkins Chief Operating Officer • Divisions 3&4 Chantal Sunter Ruth Allen RDM RDM Patients & Public & Communications Business Intelligence • Divisions 2&6 Network Clinical Divisions Division 1 • Cancer Division 2 • Diabetes • Stroke • Cardiovascular Renal Metabolic & endocrine Division 3 • Children • Genetics Division 4 • Mental Health • Dementias & neurodegenerative diseases • Neurology Division 5 • Primary care research • Oral & dental • Musculoskeletal Ageing Division 6 • ENT • Surgery • Respiratory • Critical care • Hepatology Anaesthesia & pain management Critical care Opthalmology Infectious diseases Gastroenterology Reproductive health & childbirth Haematology Health services Dermatology Public Health The Clinical Team Dr Steve Falk Clinical Director 6 Divisional Clinical Leads Prof Hugh Barr for Div 1 30 Specialty Leads Sub Specialty Leads Sue Taylor Network Consultant Nurse Clinical Research Teams NIHR CRN High Level Objectives • • • • Set up as fast as you can Recruit as many and as fast as you can All organisations involved Commercial and non commercial portfolio studies Cancer specialty specific objectives • Recruitment overall at 20% cancer incidence • Recruitment to interventional studies at 7.5% of cancer incidence • Recruitment to rare cancer studies How important is cancer on our patch? Research staff WTE per division Div 1 58 67 Div 2 Div 3 23 34 17 20 21 Div 4 Div 5 • • • • • • • Div 6 Generic • Cancer incidence 9544 242 recruiting studies £2 million (16%) Funding per incident case approx £220 Funding per recruit £800 Exceeded both recruitment targets for last 2 years Largest non commercial portfolio Benefit from continued good national and international links Chart 8: CRN: West of England Performance against Specialty goals 14/15 7000 6000 5000 4000 3000 2000 1000 0 Recruitment 2014/15 Recruitment goal 2014/15 Chart 11a: Recruitment to Cancer specialty by CRN: West of England partner organisations 2013/14 - 2015/16 † 1000 888 909 900 800 Recruitment 700 600 500 400 403 434 377 363 294 300 225 200 249 246 200 100 127 28 15 15 25 36 4 0 Gloucestershire Hospitals Great Western Hospitals North Bristol NHS Trust Royal United Hospitals University Hospitals Weston Area Health NHS NHS Foundation Trust NHS Foundation Trust Bath NHS Foundation Bristol NHS Foundation Trust Trust Trust 2013/2014 2014/2015 2015/2016 (April 2015) Recruiting studies Study Acronym/Title Taunton and Somerset Gloucestershire Royal United NHS Hospitals NHS Hospital Bath Foundation Foundation Trust NHS Trust Trust ART DECO De-ESCALaTE HPV 5 3 Developing a core information set for consent to oral cancer surgery HeadandNeck5000 – now closed IoN 12 12 8 3 NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer) Grand Total 20 15 8 University Hospitals Bristol NHS Foundation Trust Grand Total 3 3 9 17 98 98 93 125 7 10 2 2 212 255 National Portfolio • 6 studies in set up. Only 1 open to new sites EORTC 1209EnTF A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy. 43 Studies on National Portfolio Only a few open to new sites HOPON - (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): A Randomised Controlled Trial of Hyperbaric Oxygen to prevent Osteoradionecrosis of the Irradiated Mandible. Closing 2018, 62% recruited. DAHANCA 21 - Hyperbaric oxygen treatment of mandibular osteoradionecrosis. A randomized clinical study. Closes Dec 2018. 2% recruited so far. Head and Neck Cancer: molecular, cellular and immunological mechanisms Investigation of the molecular and genetic mechanisms promoting oral cancer development and progression. Closing March 2020, 45% recruited. Head and neck skin malignancy - Investigating molecular and cellular mechanisms of head and neck skin malignancy. Closing April 2019, 12% recruited so far. IoN Is ablative radio-iodine necessary for low risk differentiated thyroid cancer patients. Closing May 2016, 45% recruited. 2 further studies open to new sites but nearing closure date. Cancer Subspecialty Research Leads • Within each network 13 subspecialty research lead roles are identified, mapping onto the national Clinical Studies Groups with the aim of: – Providing link between local network and CSGs – Promoting the research agenda to clinical colleagues across the network – Advising on portfolio planning locally – Attendance at annual meeting to discuss portfolio planning and delivery and horizon scan for new studies – Supporting the research delivery manager for the cancer specialty • Role very similar to SSG Research Lead role 17 National Clinical Studies Groups Psychosocial & Survivorship Brain Tumours Head & CSG Palliative & Neck Supportive CSG Care Sarcoma CSG Breast Cancer CSG Imaging Adv. panel Lung Cancer CSG Upper GI Biomarkers Adv. panel Cancer CSG Colorectal Cancer Consumer CSG Melanoma Liaison PPI Kidney CSG Group Cancer Primary CSG Lymphoma Care Bladder CSG Cancer Screening, Testis CSG Haematol. Prevention & Cancer CSG Prostate Gynae Early Diagnosis CSG Children’s Cancer Cancer Cancer & CSG CSG Teenage & Leukaemia Young Adult CTRad (Radiotherapy) LCRN (x15) CRN WE Exec Board Partnership Group Clin. Advisory Group Clinical Director COO Division 1 Clinical Lead Division 1 RDM [ +/- other clinical roles] 13 LCRN Subspecialty Leads: •Brain cancer •H&N cancer •Lung cancer •Breast cancer •Sarcoma •Skin Cancer •Children/young people •Upper GI cancer •Colorectal cancer •Urological cancer •Gynae cancer •Haem/lymphoma •Pall/Supportive & Psychosocial Research Delivery Teams Call for H&N sub-specialty lead in CRN - West of England • Each SSG already has a research lead • We are looking for a research lead in each tumour site to represent the network locally and nationally in terms of developing and supporting the portfolio and providing clinical specialty support to the Research Delivery Manager and Principal Investigators across the network • Expenses to attend national meetings will be met by the network • Discussion: – Your current research lead continuing and taking on the network representation and/or – The nomination of a West of England research lead who will take on network representation 20 Contact & reference details • [email protected] • [email protected] • http://csg.ncri.org.uk/portfolio-maps/ • https://www.edge.nhs.uk/Account/Index?ReturnUrl=%2f • http://www.crn.nihr.ac.uk/can-help/fundersacademics/nihrcrn-portfolio/ 21